idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
09/10/2018 17:00

Special Antibodies Could Lead to HIV Vaccine

Kurt Bodenmüller Kommunikation
Universität Zürich

    Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers from the University of Zurich and the University Hospital Zurich have now shown that the genome of the HI virus is a decisive factor in determining which antibodies are formed.

    A small number of people who are infected with HIV-1 produce very special antibodies. These antibodies do not just fight one virus strain, but neutralize almost all known virus strains. Research into developing an HIV vaccine focuses on discovering the factors responsible for the production of such antibodies.

    HIV-1 genome influences immune reaction

    A Swiss research team led by the University of Zurich (UZH) and University Hospital Zurich (USZ) has been searching for these factors for years. Several have already been identified: For example, the virus load and the diversity of the viruses, the duration of the infection, and the ethnicity of the affected person can all influence the body’s immune response. “In our new study, we were able to identify another factor: The genome of the HI virus,” says Huldrych Günthard, deputy director of the Department of Infectious Diseases and Hospital Epidemiology at USZ.

    Antibody response of transmission pairs

    The starting point for the researchers was the data and biobanked blood samples of around 4,500 HIV-infected people, recorded in the Swiss HIV Cohort Study and the Zurich Primary HIV Infection Study. In total the researchers found 303 potential transmission pairs – i.e. pairs of patients for whom the similarity of the viruses’ genomic RNA indicated that they were probably infected with the same virus strain. “By comparing the immune response of these pairs of patients, we were able to show that the HI virus itself has an influence on the extent and specificity of the antibody reactions,” explains the study’s first author Roger Kouyos, research group leader at the Department of Infectious Diseases and Hospital Epidemiology at USZ.

    Special envelope proteins provide broad protection

    Antibodies acting against HIV bind to proteins found on the surface of the virus. These envelope proteins differ according to virus strain and subtype. The researchers therefore examined more closely a patient pair with very similar virus genomes and at the same time very strong activity of broadly neutralizing antibodies. “We discovered that there must be a special envelope protein that causes an efficient defense,” explains Alexandra Trkola, virologist and head of the Institute of Medical Virology at UZH.

    Search for an ideal envelope protein continues

    In order to be able to develop an effective vaccine against HIV-1, it is necessary to pinpoint the envelope proteins and virus strains that lead to the formation of broadly acting antibodies. It is therefore planned to widen the search. “We have found one candidate. Based on that, we now want to begin developing an immunogen ourselves,” adds Trkola.


    Contact for scientific information:

    Prof. Alexandra Trkola, PhD
    Institute of Medical Virology
    University of Zurich
    Phone: +41 44 634 53 80
    E-mail: trkola.alexandra@virology.uzh.ch

    Prof. Roger Kouyos, PhD
    Department of Infectious Diseases and Hospital Epidemiology
    UniversityHospital Zurich
    Phone: +41 44 255 36 10
    E-mail: roger.kouyos@usz.ch

    Prof. Huldrych Günthard, M.D.
    Department of Infectious Diseases and Hospital Epidemiology
    UniversityHospital Zurich
    Phone: +41 44 255 34 50
    E-mail: huldrych.guenthard@usz.ch


    Original publication:

    Roger D. Kouyos, et. al. Tracing HIV-1 strains that imprint broadly neutralising antibody responses. Nature. September 10, 2018. DOI: 10.1038/s41586-018-0517-0


    More information:

    http://www.media.uzh.ch/en/Press-Releases/2018/HIV-Vaccine.html


    Images

    An antibody (dark grey) is binding to an HIV envelope protein (coloured) on the surface of the virus (light grey).
    An antibody (dark grey) is binding to an HIV envelope protein (coloured) on the surface of the virus ...
    Source: UZH


    Criteria of this press release:
    Journalists, Scientists and scholars
    Biology, Medicine
    transregional, national
    Research results, Scientific Publications
    English


     

    An antibody (dark grey) is binding to an HIV envelope protein (coloured) on the surface of the virus (light grey).


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).